Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Berger-Becvar A"'
Autor:
Ingeborg Menzl, Tinghu Zhang, Angelika Berger-Becvar, Reinhard Grausenburger, Gerwin Heller, Michaela Prchal-Murphy, Leo Edlinger, Vanessa M. Knab, Iris Z. Uras, Eva Grundschober, Karin Bauer, Mareike Roth, Anna Skucha, Yao Liu, John M. Hatcher, Yanke Liang, Nicholas P. Kwiatkowski, Daniela Fux, Andrea Hoelbl-Kovacic, Stefan Kubicek, Junia V. Melo, Peter Valent, Thomas Weichhart, Florian Grebien, Johannes Zuber, Nathanael S. Gray, Veronika Sexl
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-15 (2019)
Cyclin-dependent kinases are deregulated in blood cancers. Here, the authors show that CDK8, independent of its kinase activity, regulates mTOR signalling for the maintenance of BCR-ABL1+ leukemia, and that the dual inhibition of CDK8 and mTOR signal
Externí odkaz:
https://doaj.org/article/90ab601100a74a6da15edcbbea0a9c4e
Autor:
Geletu, M., Mohan, R., Arulanandam, R., Berger-Becvar, A., Nabi, I.R., Gunning, P.T., Raptis, L.
Publikováno v:
In BBA - Molecular Cell Research May 2018 1865(5):794-802
Autor:
Yanke Liang, Junia V. Melo, Karin Bauer, Ingeborg Menzl, Nicholas Kwiatkowski, Johannes Zuber, Vanessa M. Knab, Veronika Sexl, Michaela Prchal-Murphy, Tinghu Zhang, Stefan Kubicek, Peter Valent, Iris Z. Uras, Anna Skucha, Florian Grebien, Eva Grundschober, Gerwin Heller, Thomas Weichhart, Nathanael S. Gray, Angelika Berger-Becvar, Yao Liu, Mareike Roth, Daniela A. Fux, Andrea Hoelbl-Kovacic, Leo Edlinger, John M. Hatcher, Reinhard Grausenburger
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-15 (2019)
Nature Communications
Nature Communications
Cyclin-dependent kinases (CDKs) are frequently deregulated in cancer and represent promising drug targets. We provide evidence that CDK8 has a key role in B-ALL. Loss of CDK8 in leukemia mouse models significantly enhances disease latency and prevent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3e2932886a8bb5546af466f37450724
http://link.springer.com/article/10.1038/s41467-019-12656-x
http://link.springer.com/article/10.1038/s41467-019-12656-x
Autor:
Rozanne Arulanandam, Patrick T. Gunning, Reva Mohan, Angelika Berger-Becvar, Ivan R. Nabi, Mulu Geletu, Leda Raptis
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1865:794-802
Caveolin-1 (Cav1) is an integral plasma membrane protein and a complex regulator of signal transduction. The Signal Transducer and Activator of Transcription-3 (Stat3) is activated by a number of receptor and non-receptor tyrosine kinases and is posi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd3f83727b245d1aadf1d15f316af469
https://doi.org/10.1016/j.bbamcr.2018.02.004
https://doi.org/10.1016/j.bbamcr.2018.02.004
Autor:
Ji Sung Park, Gary Tin, Elizabeth Heyes, Anna Orlova, Bettina Wingelhofer, Abbarna A. Cumaraswamy, Dávid Bajusz, Florian Grebien, Barbara Maurer, Charles-Hugues Lardeau, Elvin D. de Araujo, Patrick T. Gunning, Irina Sadovnik, György M. Keserű, Angelika Berger-Becvar, Frank Ruge, Patricia Freund, Stefan Kubicek, Peter Valent, Richard Moriggl, Siawash Ahmar
Publikováno v:
Leukemia
The transcription factor STAT5 is an essential downstream mediator of many tyrosine kinases (TKs), particularly in hematopoietic cancers. STAT5 is activated by FLT3-ITD, which is a constitutively active TK driving the pathogenesis of acute myeloid le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cbd9fbacdbb6f70dcb6408350e6475f
https://doi.org/10.1038/s41375-017-0005-9
https://doi.org/10.1038/s41375-017-0005-9
Autor:
Orlova, Anna, Wingelhofer, Bettina, Neubauer, Heidi A., Maurer, Barbara, Berger-Becvar, Angelika, Keserű, György Miklós, Gunning, Patrick T., Valent, Peter, Moriggl, Richard
Publikováno v:
Expert Opinion on Therapeutic Targets
Introduction: Hematopoietic neoplasms are often driven by gain-of-function mutations of the JAK-STAT pathway together with mutations in chromatin remodeling and DNA damage control pathways. The interconnection between the JAK-STAT pathway, epigenetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::26ce75dea73f0f10b6f4611674db998c
http://europepmc.org/articles/PMC5743003
http://europepmc.org/articles/PMC5743003
Autor:
Shiva Farhangi, Elvin D. de Araujo, Ji Sung Park, Angelika Berger-Becvar, Patrick T. Gunning, Pimyupa Manaswiyoungkul, Karen Yuen, Lubna Abu-Jazar, Johan Israelian
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 143:159-167
The development of STAT protein-specific inhibitors has been the focus of a number of drug discovery programs. STAT activation occurs through phosphorylation at the STAT SH2 domain, resulting in dimerization, translocation to the nucleus, and transcr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e77dda55b971663c174ad76d2b2008a
https://doi.org/10.1016/j.jpba.2017.04.052
https://doi.org/10.1016/j.jpba.2017.04.052
Autor:
Georg Greiner, Lars Gille, Christine Brostjan, Zsuzsanna Bago-Horvath, Wael Al-Zoughbi, Eva Grundschober, Andreas Spittler, Andrea Hoelbl-Kovacic, Leo Edlinger, Gerald Hoefler, Angelika Berger-Becvar, Gregor Hoermann, Ingeborg Menzl, Richard Moriggl, Veronika Sexl
Publikováno v:
British Journal of Haematology
Summary The p21‐activated kinases (PAKs) are key nodes in oncogenic signalling pathways controlling growth, survival, and motility of cancer cells. Their activity is increased in many human cancers and is associated with poor prognosis. To date, PA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::931ff2bba2527509f5957a5431602c21
http://europepmc.org/articles/PMC5655792
http://europepmc.org/articles/PMC5655792
Autor:
Mulu Geletu, Angelika Berger-Becvar, Ashley A. Adile, William L. Heaton, Stephen F. Konieczny, Justyna M. Gawel, Patrick T. Gunning, Andrew E. Shouksmith, Melissa L. Fishel, Sheila K. Singh, Thomas O'Hare, Michael W. Deininger, H. Artee Luchman, David Bakhshinyan, Michelle Grimard, Chitra Venugopal, Yasir S. Raouf, Fenil Shah, Samuel Weiss, Elvin D. de Araujo
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, incurable cancer with a 20% 1 year survival rate. While standard-of-care therapy can prolong life in a small fraction of cases, PDAC is inherently resistant to current treatments, and novel th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1efc7d1410f4a07409fa1893dcd093a1
https://europepmc.org/articles/PMC7190078/
https://europepmc.org/articles/PMC7190078/
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.